A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1/2
42
about 7.4 years
18–70
3 sites in CO, NC, TN
What this study is about
Researchers are testing a new treatment, IOV-3001, for adults with advanced melanoma who are also receiving lifileucel. The trial will evaluate the safety and effectiveness of IOV-3001 as part of this treatment regimen.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive IOV-3001
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety and Tolerability
Secondary: Complete Response (CR) rate, Disease Control Rate (DCR), Duration of Response (DOR), Overall Response Rate (ORR), Overall Survival (OS), Pharmacodynamic (PD) Profile of IOV-3001, Pharmacokinetics (PK) profile of IOV-3001, Progression-Free Survival (PFS)
Oncology